According to Intra-Cellular Therapies's latest financial reports the company's current revenue (TTM) is $0.46 B. In 2022 the company made a revenue of $0.24 B an increase over the years 2021 revenue that were of $81.7 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.46 B | 85.51% |
2022 | $0.24 B | 204.91% |
2021 | $81.7 M | 262.65% |
2020 | $22.53 M | 37071.49% |
2019 | $0.06 M | |
2018 | N/A | |
2017 | N/A | |
2016 | N/A | -100% |
2015 | $0.03 M | -94.4% |
2014 | $0.54 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Xencor XNCR | $0.16 B | -63.58% | ๐บ๐ธ USA |
MediciNova MNOV | $1 M | -99.78% | ๐บ๐ธ USA |
Curis CRIS | $10.02 M | -97.83% | ๐บ๐ธ USA |